Novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients

doi:10.5306/wjco.v12.i10.947

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4926)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

238

WORD

182

HTML

1762

Figures (1-3)

186

Tables (1-5)

216

Sum=2584

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

280

Download

779

Sum=1059

Publishing Process of This Article

Item

Count

Browse

418

Download

865

Sum=1283

Oct 24, 2021 (publication date) through Aug 31, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Clin Oncol. Oct 24, 2021; 12(10): 947-959
Published online Oct 24, 2021. doi: 10.5306/wjco.v12.i10.947

Full Size Figure Download Figure

Figure 1 Qualitative screening of kynurenine by dot–immune binding assay in control, grade II, grade III, and grade IV samples; red arrow indicates the presence of immune-complex. A: Control; B: Grade II; C: Grade III; D: Grade IV. KYN: Kynurenine; CON: Control; G: Grade.

Citation: Gandhi P, Shrivastava R, Garg N, Sorte SK. Novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients . World J Clin Oncol 2021; 12(10): 947-959
URL: https://www.wjgnet.com/2218-4333/full/v12/i10/947.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i10.947